Rntl.Dh

RNTL.DH maintains a debt-to-equity ratio of 0.52, indicating a moderate reliance on debt financing, and a current ratio of 1.37, suggesting adequate short-term liquidity to cover its obligations. However, the company's free cash flow is negative at -1.46 billion BDT, and capital expenditures are substantial at -5.95 billion BDT, signaling significant reinvestment in operations. The company's liquidity position is assessed as medium risk, with a key flag indicating that net cash is negative after subtracting total debt.

In terms of profitability, RNTL.DH reports a return on equity (ROE) of 10.67% and a return on assets (ROA) of 6.37%, both of which are strong indicators of efficient capital utilization and asset management. The company's operating income of 5.32 billion BDT and net income of 3.62 billion BDT reflect a healthy margin structure, although the gross profit margin of 44.23% (16.68 billion BDT on 37.71 billion BDT revenue) suggests room for improvement in cost control.

Geographically and segment-wise, RNTL.DH's revenue concentration is not disclosed in the available data, but the company's operations are primarily centered on pharmaceuticals. The absence of detailed segment or geographic breakdowns limits the ability to assess exposure to specific markets or product lines.

Looking ahead, RNTL.DH is projected to maintain a stable revenue trajectory, with no significant growth or decline expected in the current or next fiscal year. The company's capital expenditures are expected to remain high, driven by ongoing investments in production capacity and R&D. Analysts have assigned a mean price target of 642.33 BDT, with a median of 617.00 BDT, and a mean recommendation of 2.00 (indicating a "buy" rating).

The risk assessment for RNTL.DH highlights a medium liquidity risk and a low dilution risk. The company's dilution potential is minimal, with no near-term pressure expected, and no recent issuance or shelf registration activity reported. However, the negative free cash flow and high capital expenditures may pose challenges in maintaining financial flexibility.

Recent events and filings for RNTL.DH do not include any material changes in business strategy or regulatory actions. The company's financial performance remains consistent with its historical trends, and no significant earnings surprises or management changes have been reported in the latest available data.